KYORIN PHARMACEUTICAL CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,695 JPY | -0.12% |
|
-0.88% | -4.78% |
| 2023 | ATyr Pharma to Obtain $10 Million in Milestone Payment After Partner Starts Dosing Patients in Lung Disease Study in Japan | MT |
| 2021 | KYORIN Holdings, Inc.(TSE:4569) dropped from S&P Japan 500 | CI |
| Sales 2024 | 120B 763M | Sales 2025 * | 125B 795M | Capitalization | 97.49B 622M |
|---|---|---|---|---|---|
| Net income 2024 | 5.32B 33.97M | Net income 2025 * | 5.09B 32.48M | EV / Sales 2024 | 0.87 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.78 x |
| P/E ratio 2024 |
19.5
x | P/E ratio 2025 * |
19.1
x | Employees | 2,138 |
| Yield 2024 |
2.87% | Yield 2025 * |
3.06% | Free-Float | 57.17% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.99% | ||
| 1 week | -1.34% | ||
| Current month | -7.72% | ||
| 1 month | -4.50% | ||
| 3 months | -3.85% | ||
| 6 months | -4.50% | ||
| Current year | -4.66% |
1 week
1 697.00
1 735.00
1 month
1 697.001 843.00
Current year
1 697.001 880.00
1 year
1 697.001 880.00
3 years
1 639.001 924.00
5 years
1 630.002 600.00
10 years
1 630.003 040.00
| Managers | Title | Age | Since |
|---|---|---|---|
Minoru Hogawa
CHM | Chairman | 70 | 05-12-31 |
Yutaka Ogihara
PSD | President | 56 | 11-05-31 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ken Shigematsu
BRD | Director/Board Member | 75 | 17-05-31 |
Yutaka Ogihara
PSD | President | 56 | 11-05-31 |
| Comptroller/Controller/Auditor | 70 | 06-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.23% | 19 M€ | +9.49% | ||
| 0.02% | 17 M€ | +11.76% | - | |
| 0.01% | 140,441 M€ | +16.91% | ||
| 0.01% | 20,360 M€ | +15.77% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 1,695 | -0.12% | 29 000 |
| 24-05-22 | 1,697 | -0.99% | 107,500 |
| 24-05-21 | 1,714 | -0.06% | 70,400 |
| 24-05-20 | 1,715 | +0.18% | 84,400 |
| 24-05-17 | 1,712 | +0.12% | 107,100 |
Delayed Quote Japan Exchange, May 22, 2024 at 02:00 am EDT
More quotes
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
Sector
Pharmaceuticals
Calendar
2024-07-30
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
1
Last Close Price
1,697
JPY
Average target price
1,300
JPY
Spread / Average Target
-23.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.66% | 631M | |
| +37.74% | 723B | |
| +32.22% | 598B | |
| -2.07% | 364B | |
| +20.25% | 331B | |
| +2.99% | 288B | |
| +16.60% | 244B | |
| +9.77% | 210B | |
| -5.15% | 208B | |
| +7.43% | 169B |
- Stock Market
- Equities
- 4569 Stock
